Skip to main content

Table 2 Grade ≥ 3 adverse events occurring in randomized phase III trials of bevacizumab in advanced ovarian cancer

From: Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review

Grade ≥ 3 AE, % GOG-0218[21] ICON7[22] OCEANS[41] AURELIA[26]
CP + placebo CP + Bev CP + Bev → Bev CP CP + Bev → Bev CG + placebo CG + Bev CTx CTx + Bev
(n = 601) (n = 607) (n = 608) (n = 753) (n = 745) (n = 233) (n = 247) (n = 182) (n = 179)
Neutropenia 57.7a 63.3a 63.3a 15 17
Pain 41.6b 41.5b 47.0b
Thrombocytopenia 2 3 34 40
Hypertension 7.2b 16.5b 22.9b <1 6 0.4 17.8
VTE 5.8c 5.3c 6.7c 2 4 4 3
Febrile neutropenia 3.5c 4.9c 4.3c 2 3 1 1
Proteinuria 0.7 0.7 1.6 <1 1 0.9 9.7
Bleeding (non-CNS) 0.8 1.3 2.1 <1 1 0.9 5.7 1 1
Wound healing complications 2.8c 3.6c 3.0c <1 1
ATE 0.8c 0.7c 0.7c 1 3 0 2
GI events 1.2b 2.8b 2.6b <1 1 0 0
Epistaxis 0.4 4.9
Abscess/fistula 1 1 0.4c 1.6c
RPLS 0 0.2c 0.2c 0 0 0 0.8c 0 1
CHF <1 <1 1 1
CNS bleeding 0 0 0.3c 0 <1
  1. AE = adverse event. ATE = arterial thromboembolic event. Bev = bevacizumab. C = carboplatin. CHF = congestive heart failure. CNS = central nervous system. CTx = chemotherapy. G = gemcitabine. GI = gastrointestinal. P = paclitaxel. RPLS = reverse posterior leukoencephalopathy syndrome. VTE = venous thromboembolic event.
  2. aGrade ≥ 4.
  3. bGrade ≥ 2.
  4. cAll grades.